期刊文献+

信迪利单抗联合FOLFOX4方案对胃癌患者疗效及对免疫功能、Foxa2、p27^(kip1)的影响

Efficacy of Sintilimab Combined with FOLFOX4 Regimen in Patients with Gastric Cancer and Its Effect on Immune Function,Foxa2 and p27^(kip1)
下载PDF
导出
摘要 目的 探讨信迪利单抗联合FOLFOX4方案对胃癌患者疗效及对免疫功能、Foxa2、p27^(kip1)影响。方法 非随机选取2022年1月—2023年12月牡丹江医科大学附属红旗医院收治的96例晚期胃癌患者作为研究对象,按照治疗方式不同分为观察组和对照组,各48例。对照组采用FOLFOX4方案治疗,观察组增加信迪利单抗治疗。评估两组患者临床疗效、肿瘤标志物水平、免疫功能指标、Foxa2与p27^(kip1)表达水平、不良反应。结果 观察组患者总有效率为81.25%(39/48),高于对照组的60.42%(29/48),差异有统计学意义(χ^(2)=2.978,P<0.05)。治疗后,观察组癌胚抗原、细胞角蛋白、错配修复蛋白6水平均低于对照组,差异有统计学意义(P均<0.05)。治疗后,观察组免疫功能指标均优于对照组,差异有统计学意义(P均<0.05)。治疗后,观察组Foxa2、p27^(kip1)表达水平均高于对照组,差异有统计学意义(P均<0.05)。两组患者不良反应发生率比较,差异无统计学意义(P>0.05)。结论 信迪利单抗联合FOLFOX4方案对胃癌患者疗效较好,可降低肿瘤标志物水平,改善患者免疫功能和Foxa2、p27^(kip1)表达水平,安全性良好。 Objective To investigate the effect of sintilimab combined with FOLFOX4 regimen on immune function,Foxa2 and p27^(kip1) in patients with gastric cancer.Methods A total of ninety-six patients with advanced gastric cancer admitted to Affiliated Hongqi Hospital of Mudanjiang Medical University from January 2022 to December 2023 were non-randomly selected as the research objects.According to different treatment methods,they were divided into obser-vation group and control group,with forty-eight cases in each group.The control group was treated with FOLFOX4 regimen,and the observation group was treated with sintilimab.The clinical efficacy,immune function,tumor markers,Foxa2,p27^(kip1) and adverse reaction of the two groups were evaluated.Results The total effective rate of the observa-tion group was 81.25%(39/48),which was higher than 60.42%(29/48)of the control group,and the difference was sta-tistically significant(χ^(2)=2.978,P<0.05).After treatment,the levels of carcinoembryonic antigen,cytokeratin and mis-match repair protein 6 in the observation group were lower than those in the control group,and the differences were statistically significant(all P<0.05).After treatment,the immune function indexes of the observation group were better than those of the control group,and the differences were statistically significant(all P<0.05).After treatment,the ex-pression levels of Foxa2 and p27^(kip1) in the observation group were higher than those in the control group,and the dif-ferences were statistically significant(both P<0.05).There was no significant difference in the incidence of adverse re-actions between the two groups(P>0.05).Conclusion Sintilimab combined with FOLFOX4 regimen has a good effect on patients with gastric cancer,reduces the level of tumor markers,improves the immune function and the expression levels of Foxa2 and p27^(kip1),and has good safety.
作者 高俊霞 郝琳娜 杨晓霞 GAO Junxia;HAO Linna;YANG Xiaoxia(Department of General Medical,Affiliated Hongqi Hospital of Mudanjiang Medical University,Mudanjiang 157011,Heilongjiang,China;Outpatient Department,Affiliated Hongqi Hospital of Mudanjiang Medical University,Mudanji-ang 157011,Heilongjiang,China;Health Management Service Center,Affiliated Hongqi Hospital of Mudanjiang Medical University,Mudanjiang 157011,Heilongjiang,China)
出处 《系统医学》 2024年第19期18-22,共5页 Systems Medicine
基金 黑龙江省卫生健康委科研课题(20210303030310)。
关键词 胃癌 信迪利单抗 奥沙利铂 氟尿嘧啶 亚叶酸钙 临床疗效 免疫功能 Gastric cancer Sindilumab Oxaliplatin Fluorouracil Calcium folinate Clinical efficacy Immune function
  • 相关文献

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部